Willame, Corinne http://orcid.org/0000-0002-6310-6019
Dodd, Caitlin
van der Aa, Lieke
Picelli, Gino
Emborg, Hanne-Dorthe
Kahlert, Johnny
Gini, Rosa
Huerta, Consuelo
Martín-Merino, Elisa
McGee, Chris
de Lusignan, Simon
Roberto, Giuseppe
Villa, Marco
Weibel, Daniel
Titievsky, Lina
Sturkenboom, Miriam C. J. M.
Funding for this research was provided by:
Innovative Medicines Initiative
Article History
Accepted: 2 December 2020
First Online: 19 January 2021
Declarations
:
: The Innovative Medicines Initiative Joint Undertaking funded this project under ADVANCE Grant agreement number 115557, resources of which were composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and in kind contributions from European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies.
: At the time of the study and manuscript development, Corinne Willame worked part time with the GlaxoSmithKline (GSK) group of companies and declares not to receive any financial support from the GSK group of companies for the submitted work. At the time of the study and manuscript development, Lina Titievsky was a Pfizer employee. Rosa Gini is employed by ARS, a public health agency that conducts or participates in pharmacoepidemiology studies. The budget of ARS is partially sustained by such studies. Simon de Lusignan has been a member of Advisory Boards for Sanofi and Seqirus, and has received funding for vaccine-related researches from GSK, Seqirus, and Takeda. Daniel Weibel has been a consultant for GSK’s malaria vaccine program. Miriam Sturkenboom is principal investigator of post-authorization safety studies requested by the European Medicines Agency, for Novartis, none of which were related to the topic described. Caitlin Dodd, Lieke van der Aa, Gino Picelli, Hanne-Dorthe Emborg, Johnny Kahlert, Consuelo Huerta, Elisa Martín-Merino, Chris McGee, Giuseppe Roberto, and Marco Villa declare they have no conflicts of interest.
: For this type of study, governance approval is mandatory to access data sources.
: Not applicable.
: Not applicable.
: Not applicable.
: Data are available from the DAPs of each of the participating data sources for researchers who meet the criteria to access confidential data. The minimal underlying dataset for replication would require interested researchers to contact each individual listed for access to their data.
: All authors contributed equally to the work submitted.